Afuco™ Anti-LOXL2 ADCC Therapeutic Antibody (Simtuzumab), ADCC Enhanced
This product is an ADCC enhanced antibody produced by our Afuco™ platform. Recombinant humanized antibody expressed in CHO binding to human LOXL2. Simtuzumab is a humanized monoclonal antibody designed for the treatment of fibrosis. It binds to LOXL2 and acts as an immunomodulator.
| Supplier | Creative Biolabs |
|---|---|
| Product # | AFC-TAB-890 |
| Pricing | Inquiry |
| Host | Human |
| Target | LOXL2 |
| Species Reactivity | Human |
| Type | ADCC enhanced antibody |
| Applications | FC, IP, ELISA, Neut, FuncS |
| Storage | Store at +4°C short term (1-2 weeks). Aliquot and store at -20°C long term. Avoid repeated freeze/thaw cycles. |